VEGFA and nonpapillary renal cell carcinoma: Current standard care for metastatic ccRCC primarily involves tyrosine receptor kinase inhibitor drugs (VEGF-TKI) targeting vascular endothelial growth factor (VEGF) receptors, such as sunitinib and sorafenib [7, 8].